title: Preparation of TH227-labeled radioimmunoconjugates, assessment of serum stability and antigen binding ability.
abstract: In this study, the feasibility of constructing radioimmunoconjugates by using the novel therapeutic candidate alpha-emitter, (227)Th, was evaluated. By use of the bifunctional chelator, p-SCN-benzyl-DOTA, (227)Th was conjugated to the two monoclonal antibodies, rituximab and trastuzumab. Their stability in 80% fetal bovine serum at 37 degrees C was measured. The immunoreactive fractions were determined by using CD20- and HER/2-positive cells, respectively. The overall labeling yield spanned from 6% to 17%. The radioimmunoconjugates demonstrated a relevant stability in serum and showed appropriate antigen-binding abilities.
authors.affiliation: Department of Radiation Biology, University of Oslo and The Norwegian Radium Hospital, Oslo, Norway.
authors.forename: Roy H
authors.initials: RH
authors.lastname: Larsen
authors.forename: Jorgen
authors.initials: J
authors.lastname: Borrebaek
authors.forename: Jostein
authors.initials: J
authors.lastname: Dahle
authors.forename: Katrine B
authors.initials: KB
authors.lastname: Melhus
authors.forename: Cecilie
authors.initials: C
authors.lastname: Krogh
authors.forename: Miriam H
authors.initials: MH
authors.lastname: Valan
authors.forename: Oyvind S
authors.initials: OS
authors.lastname: Bruland
mesh_terms: D000911:Antibodies, Monoclonal / Q000097:blood; D000941:Antigens; D045744:Cell Line, Tumor; D004355:Drug Stability; D006573:Heterocyclic Compounds, 1-Ring; D006801:Humans; D018796:Immunoconjugates / Q000097:blood*; D007202:Indicators and Reagents; D013910:Thorium / Q000097:blood / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D000941:Antigens; D006573:Heterocyclic Compounds, 1-Ring; D018796:Immunoconjugates; D007202:Indicators and Reagents; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; D013910:Thorium